scholarly article | Q13442814 |
P356 | DOI | 10.1111/DDG.13321 |
P698 | PubMed publication ID | 28872233 |
P50 | author | Selma Ugurel | Q61525329 |
Jürgen C Becker | Q87595653 | ||
Dirk Schadendorf | Q32649390 | ||
P2093 | author name string | Cathrin Ritter | |
Ioana Cosgarea | |||
P2860 | cites work | KIT gene mutations and copy number in melanoma subtypes | Q46267082 |
Transient MEK inhibitor-associated retinopathy in metastatic melanoma. | Q50455744 | ||
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study | Q27276774 | ||
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 | ||
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 | ||
Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition | Q36059811 | ||
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway | Q36109039 | ||
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition | Q37237619 | ||
NF1 Mutations Are Common in Desmoplastic Melanoma | Q37286915 | ||
KIT as a therapeutic target in metastatic melanoma | Q37701887 | ||
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma | Q38148747 | ||
Update on primary mucosal melanoma. | Q38210789 | ||
Survival of patients with advanced metastatic melanoma: The impact of novel therapies | Q38680472 | ||
Developments in targeted therapy in melanoma | Q38786472 | ||
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations | Q38852335 | ||
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 | ||
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial | Q39537308 | ||
Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. | Q40406211 | ||
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. | Q40458599 | ||
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Q40875359 | ||
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab | Q42557008 | ||
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. | Q45974368 | ||
P433 | issue | 9 | |
P304 | page(s) | 887-893 | |
P577 | publication date | 2017-09-01 | |
P1433 | published in | JDDG | Q15753048 |
P1476 | title | Update on the clinical use of kinase inhibitors in melanoma | |
P478 | volume | 15 |
Search more.